Study S000322

Single-centre Study Investigating the Role of Long-acting Subcutaneous Glucose-dependent Insulinotropic Polypeptide Receptor Agonist (GIP RA) in Combination With Long-acting Subcutaneous Amylin Receptor Agonist on Gastrointestinal Tolerability in Participants With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07411560
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: RECRUITING
Enrollment: 100
Start: 2026-02-09
Primary completion: 2027-01-26
Lead sponsor: Novo Nordisk A/S
Conditions: Overweight; Obese
Interventions: DRUG:Glucose-dependent Insulinotropic Polypeptide (GIP); DRUG:Cagrilintide; DRUG:Placebo GIP
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1324-3573

Registered primary outcomes

Number of Treatment Emergent Adverse Events (TEAEs) nausea, vomiting and diarrhoea [From first investigational medicinal products (IMP) administration (visit 2, day 1 or visit 9, day 74) to the end of treatment visit (Visit 2, day 16 or Visit 9, day 89)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.